login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PMV PHARMACEUTICALS INC (PMVP) Stock News
USA
- NASDAQ:PMVP -
US69353Y1038
-
Common Stock
1.4
USD
-0.04 (-2.78%)
Last: 10/17/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PMVP Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
a month ago - By: Benzinga
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
a month ago - By: Benzinga
- Mentions:
ACTU
CAMP
GNPX
TVTX
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
a year ago - By: BusinessInsider
PMVP Stock Earnings: PMV Pharma Beats EPS for Q2 2024
a year ago - By: InvestorPlace
PMVP Stock Earnings: PMV Pharma Beats EPS for Q2 2024
a year ago - By: InvestorPlace
PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024
a month ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
2 months ago - By: The Motley Fool
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
2 months ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
a year ago - By: BusinessInsider
PMVP Stock Earnings: PMV Pharma Beats EPS for Q1 2024
5 months ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
5 months ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
8 months ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
8 months ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
a year ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
a year ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
a year ago - By: Foundation Medicine
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
a year ago - By: PMV Pharmaceuticals, Inc.
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
a year ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
2 years ago - By: Seeking Alpha
PMV to focus on lead drug, slashes workforce by 30% (NASDAQ:PMVP)
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
2 years ago - By: Seeking Alpha
PMV Pharmaceuticals names Michael Carulli as CFO (NASDAQ:PMVP)
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
2 years ago - By: Seeking Alpha
Ladenburg Thalmann starts PMV Pharmaceuticals at buy (NASDAQ:PMVP)
2 years ago - By: PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
Please enable JavaScript to continue using this application.